SIR-Spheres® Y-90 resin microspheres are approved and indicated in over 40 countries for the treatment of patients with inoperable liver tumours. In additon to its use in metastatic Colorectal Cancer and Hepatocellular Carcinoma, a broad range of clinical experience has been gained in patients with liver metastases from Neuroendocrine Tumours, Breast Cancer, Ocular Melanoma and Pancreatic Cancer, and in Cholangiocarcinoma.
In addition, several studies are currently investigating the effect of SIR-Spheres Y-90 resin microspheres on tumours that have spread to the liver from Ocular Melanoma, Breast Cancer and Cholangiocarcinoma.
Sirtex is broadening its focus to examine the use of SIR-Spheres Y-90 resin microspheres in a number of cancers outside the liver. The first of these studies, RESIRT, is investigating its potential benefit in the treatment of primary Renal Cell Cancer.